This is a rare type of cancer that starts in the glands that make saliva, not the breast. It's a slow-growing cancer, meaning it usually doesn't spread quickly. Doctors diagnose it by looking at a small sample of the affected gland tissue under a microscope.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Mammary Analogue Secretory Carcinoma?
Mammary analogue secretory carcinoma is a rare cancer of the salivary glands, the glands that make saliva. It most often starts in the parotid gland, which sits in front of the ear and over the angle of the jaw. Less often it begins in the submandibular gland under the jaw or in the small salivary glands of the lips, cheek lining or palate. It usually appears as a painless lump that grows slowly, sometimes for months or years before someone has it checked. The name comes from its close resemblance, under the microscope and at the genetic level, to secretory carcinoma of the breast. It is not breast cancer, and it does not mean cancer has spread from the breast. Since 2017 the World Health Organization has called it simply secretory carcinoma of the salivary gland, so reports may use either name. Most of these tumors are low grade, meaning slow growing and less likely to spread, and many are found early. A minority behave more aggressively, which is why accurate diagnosis and follow-up matter.
No specific cause or lifestyle risk factor has been identified for this tumor. What defines it is a change inside the tumor cells: two genes, ETV6 and NTRK3, break and join together to form a fusion gene that drives the cells to grow. This change develops in the tumor itself. It is not inherited and is not something a person did. For salivary gland cancers in general, known risk factors include older age, past radiation treatment to the head and neck, and some workplace exposures, although most people with these cancers have no clear risk factor. Secretory carcinoma affects men and women in roughly equal numbers. It is most often diagnosed in middle age, but it also occurs in children and young adults.
Assessment usually starts with an examination of the head, neck and mouth, followed by imaging such as an MRI or CT scan to show the lump's size, its relation to nearby nerves and whether neck lymph nodes look involved. A thin-needle sample (fine needle aspiration) is the most common first biopsy for a salivary lump. This tumor is hard to recognize from a needle sample alone, because its cells look similar to other salivary tumors, especially acinic cell carcinoma. Often the diagnosis is made or confirmed only after the lump is removed. Two tests help settle it: a stain that detects the TRK (tropomyosin receptor kinase) protein made by the fusion gene, and a genetic test, often FISH (fluorescence in situ hybridization), that looks directly for the ETV6-NTRK3 fusion. Finding the fusion confirms the diagnosis and also matters later, because it determines whether targeted medicines could be used. Because salivary gland cancers are uncommon and varied, it is reasonable to ask that the tissue be reviewed by a pathologist experienced in salivary tumors.
Surgery to remove the tumor with a margin of healthy tissue is the main treatment. For a parotid tumor this means an operation on the gland called a parotidectomy. The facial nerve, which controls the muscles of facial expression, runs through the parotid, so surgeons work to preserve it. Temporary weakness of facial movement is fairly common after parotid surgery and usually improves, while lasting weakness is less common. If lymph nodes in the neck are involved, they are removed as well. Radiation therapy after surgery is generally reserved for tumors with higher-risk features, such as cancer left at the edge of the removed tissue, a high-grade appearance, spread along nerves, or involved lymph nodes. Many people with a small, completely removed, low-grade tumor need no further treatment beyond monitoring. When the cancer has spread, has come back, or cannot be removed without serious harm, the fusion gene opens another option. TRK inhibitors are pills that block the signal from the fused gene. Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) are approved in these situations for solid tumors that carry this kind of fusion, and repotrectinib (Augtyro) is a newer option. In larotrectinib's trials, most salivary tumors of this type shrank, though the numbers studied were small and long-term results are still being gathered. Common trade-offs include dizziness and changes in thinking, mood or sleep, and regular liver blood tests are needed. They can harm a pregnancy, so effective contraception is part of the plan. Clinical trials may also be an option for advanced disease.
For most people the outlook is good. Many tumors are found at an early stage and are cured by surgery, sometimes followed by radiation. When facial weakness follows parotid surgery, it usually improves over time. Surgery elsewhere in the head and neck can sometimes affect chewing, swallowing or speech, and rehabilitation such as speech therapy can help when it does. The tumor can come back in the same area, and a minority spread to neck lymph nodes or, less often, to distant organs. Recurrence is more likely when the tumor was not fully removed or shows high-grade features, and has also been seen in some younger patients. For this reason, follow-up visits with a head and neck cancer team continue for years after treatment, with examinations and imaging as recommended. For people living with advanced disease, TRK inhibitors shrink the tumor in many cases, with ongoing monitoring for side effects.
See a doctor about a lump near the ear, cheek or jaw, on the lip or inside the mouth that does not go away, even if it is painless. Arrange a prompt appointment if a lump comes with numbness or weakness in part of the face, facial pain that persists, or new trouble swallowing or opening the mouth widely. After treatment, contact your care team about a new lump in the face or neck, new facial weakness, or any other new symptom that persists, so it can be checked for recurrence. If you are taking a TRK inhibitor, report dizziness, confusion, memory or mood changes, or trouble sleeping to your oncology team.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mammary Analogue Secretory Carcinoma is like, what's helped you, or ask the community a question.